Relmada Therapeutics, Inc. (RLMD)

Current Price Range

~$7.21 – $7.36 ▲ After-Hours +2%

Previous Close

$7.21 (-0.55%)

Assessment Date

May 30, 2026

Relmada Therapeutics, Inc. (RLMD) is a clinical-stage biotech focused on developing novel therapies for central nervous system disorders and oncology. Lead candidate NDV-01 (sustained-release gemcitabine/docetaxel) is advancing toward Phase 3 for non-muscle invasive bladder cancer. The company also has sepranolone in development for compulsive disorders and Prader-Willi syndrome. Cash runway extends into 2029 (~$234M).

Swing Trade Scenarios & Risk Profiles

Scenario	Entry Point	Stop-Loss	Target(s)	Potential Return	R:R Ratio	Est. Prob.	Strategic Notes
Bullish Pullback Buy PRIMARY	$6.80 – $7.10 (Near-term support zone)	Below $6.20 – $6.40 (10–12% risk)	$9.00 (T1) $11.00–$12.00 (T2)	+25% to +65%+	1:2.0+	~55–65%	High-reward biotech setup. Strong cash position and Phase 3 timeline for NDV-01 support the bullish case.
Breakout Continuation AGGRESSIVE	Above $7.60 – $7.80 on volume	$6.90 – $7.10 zone	$9.50 (T1) $12+ (T2)	+20% to +60%+	1:2.5+	~50–60%	Momentum continuation if it breaks recent resistance. Watch for Jefferies conference updates (June 4).
Range-Bound Swing	$6.90 – $7.50	Below $6.30	$8.50 – $9.00	+15% to +25%	1:1.8	~50–60%	Lower risk consolidation while awaiting pipeline news.

Risk Management Directives

• Limit risk to 1% of total portfolio equity per trade.
• Prefer pullback entries with volume confirmation and bullish reversal patterns.
• Take partial profits at Target 1 and trail the remainder.
• Move stop to breakeven after Target 1 is reached.
• High volatility clinical-stage biotech — size positions conservatively and monitor clinical/regulatory news closely.

Strategic Conclusion: RLMD closed at $7.21 on May 29 with light volume. The stock remains in a constructive range near recent highs (~$8.00 52-week high) with a solid cash runway into 2029 and Phase 3 plans for NDV-01. Pullbacks continue to offer high-reward swing setups, though typical biotech volatility applies.

Required Financial Disclaimer

This report is for educational purposes only. Not financial advice. Trading involves substantial risk of loss. Always conduct your own research and due diligence.